Limits...
Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.

Watanabe T - Breast Cancer (2013)

Bottom Line: UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil.UFT is characterized by mild adverse events, allowing long-term treatment.The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan, twatanab@oncoloplan.com.

ABSTRACT
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.

Show MeSH

Related in: MedlinePlus

Development of oral formulations. 5-FU 5-fluorouracil, DPD dihydropyrimidine dehydrogenase, UFT tegafur plus uracil, TS-1 tegafur, CDHP (gimeracil), and Oxo (oteracil)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3824200&req=5

Fig1: Development of oral formulations. 5-FU 5-fluorouracil, DPD dihydropyrimidine dehydrogenase, UFT tegafur plus uracil, TS-1 tegafur, CDHP (gimeracil), and Oxo (oteracil)

Mentions: Tegafur, a prodrug of 5-FU, was synthesized in 1967 for injectable use. Subsequently, tegafur was found to be well absorbed after oral administration, resulting in prolonged plasma concentrations of tegafur and 5-FU. These findings led to the development of oral formulations (Fig. 1).Fig. 1


Evidence produced in Japan: tegafur-based preparations for postoperative chemotherapy in breast cancer.

Watanabe T - Breast Cancer (2013)

Development of oral formulations. 5-FU 5-fluorouracil, DPD dihydropyrimidine dehydrogenase, UFT tegafur plus uracil, TS-1 tegafur, CDHP (gimeracil), and Oxo (oteracil)
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3824200&req=5

Fig1: Development of oral formulations. 5-FU 5-fluorouracil, DPD dihydropyrimidine dehydrogenase, UFT tegafur plus uracil, TS-1 tegafur, CDHP (gimeracil), and Oxo (oteracil)
Mentions: Tegafur, a prodrug of 5-FU, was synthesized in 1967 for injectable use. Subsequently, tegafur was found to be well absorbed after oral administration, resulting in prolonged plasma concentrations of tegafur and 5-FU. These findings led to the development of oral formulations (Fig. 1).Fig. 1

Bottom Line: UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil.UFT is characterized by mild adverse events, allowing long-term treatment.The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery.

View Article: PubMed Central - PubMed

Affiliation: Department of Medicine, Hamamatsu Oncology Center, 3-6-13 Chuo, Naka-ku, Hamamatsu, Shizuoka, 430-0929, Japan, twatanab@oncoloplan.com.

ABSTRACT
Oral fluoropyrimidine anticancer agents (oral 5-fluorouracil [5-FU]) able to be used as chemotherapy for breast cancer include tegafur-uracil (UFT), tegafur-gimeracil-oteracil potassium (S-1), doxifluridine, and capecitabine. Since the 1980s, UFT has been most widely used for postoperative chemotherapy in breast cancer. UFT is an oral preparation that was designed to achieve and maintain high concentrations of 5-FU in plasma by combining tegafur, a prodrug of 5-FU, with uracil. UFT is characterized by mild adverse events, allowing long-term treatment. The prolonged maintenance of high plasma 5-FU concentrations has been suggested to inhibit micrometastases after surgery. Recently, large clinical trials conducted in Japan have shown that UFT-based postoperative chemotherapy is therapeutically useful in patients with node-negative (n0), high-risk breast cancer. We review the results of clinical trials of postoperative chemotherapy with UFT in Japan and discuss its roles and future prospects.

Show MeSH
Related in: MedlinePlus